CME Net Worth
CME Net Worth Breakdown | CME |
CME Net Worth Analysis
CME's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CME's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CME's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CME's net worth analysis. One common approach is to calculate CME's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CME's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CME's net worth. This approach calculates the present value of CME's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CME's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CME's net worth. This involves comparing CME's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CME's net worth relative to its peers.
Enterprise Value |
|
To determine if CME is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CME's net worth research are outlined below:
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| On 25th of June 2025 CME paid $ 1.25 per share dividend to its current shareholders | |
| Latest headline from cbsnews.com: High-yield savings account pros and cons to know this July |
CME Quarterly Good Will |
|
CME uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CME Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CME's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
CME Target Price Consensus
CME target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. CME's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 18 | Buy |
Most CME analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand CME stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of CME Group, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCME Target Price Projection
CME's current and average target prices are 275.08 and 271.12, respectively. The current price of CME is the price at which CME Group is currently trading. On the other hand, CME's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On CME Target Price
Know CME's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CME is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CME Group backward and forwards among themselves. CME's institutional investor refers to the entity that pools money to purchase CME's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Capital Research & Mgmt Co - Division 3 | 2025-03-31 | 4.4 M | Northern Trust Corp | 2025-03-31 | 3.8 M | Arrowstreet Capital Limited Partnership | 2025-03-31 | 3.6 M | Fidelity International Ltd | 2025-03-31 | 3.6 M | Franklin Resources Inc | 2025-03-31 | 3.4 M | Royal Bank Of Canada | 2025-03-31 | 3.3 M | Goldman Sachs Group Inc | 2025-03-31 | 3.1 M | Ubs Group Ag | 2025-03-31 | 3 M | Mitsubishi Ufj Asset Management Co.,ltd | 2025-03-31 | 2.9 M | Vanguard Group Inc | 2025-03-31 | 34.6 M | Blackrock Inc | 2025-03-31 | 32.6 M |
Follow CME's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 99.17 B.Market Cap |
|
Project CME's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.06 | |
| Return On Capital Employed | 0.11 | 0.17 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.13 | 0.13 |
When accessing CME's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CME's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CME's profitability and make more informed investment decisions.
Please note, the presentation of CME's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CME's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CME's management manipulating its earnings.
Evaluate CME's management efficiency
CME Group has Return on Asset of 0.0176 % which means that on every $100 spent on assets, it made $0.0176 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1339 %, implying that it generated $0.1339 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Equity is forecasted to decline to 0.13. At present, CME's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 104.4 B, whereas Other Assets are forecasted to decline to about 146.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 73.70 | 39.50 | |
| Tangible Book Value Per Share | (3.27) | (3.43) | |
| Enterprise Value Over EBITDA | 18.21 | 14.22 | |
| Price Book Value Ratio | 3.15 | 3.78 | |
| Enterprise Value Multiple | 18.21 | 14.22 | |
| Price Fair Value | 3.15 | 3.78 | |
| Enterprise Value | 60.2 B | 63.3 B |
CME Group has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 16.082 | Revenue | Quarterly Revenue Growth 0.104 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CME insiders, such as employees or executives, is commonly permitted as long as it does not rely on CME's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CME insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mccourt Timothy Francis over six months ago Disposition of tradable shares by Mccourt Timothy Francis of CME at 206.775 subject to Rule 16b-3 | ||
Mccourt Timothy Francis over a year ago Disposition of tradable shares by Mccourt Timothy Francis of CME at 217.5 subject to Rule 16b-3 | ||
Julie Winkler over a year ago Acquisition by Julie Winkler of 3808 shares of CME subject to Rule 16b-3 | ||
Julie Winkler over a year ago Payment of 1513 shares by Julie Winkler of CME subject to Rule 16b-3 |
CME Corporate Filings
F4 | 26th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 9th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of May 2025 Other Reports | ViewVerify | |
F5 | 5th of May 2025 The annual filing required by the Securities and Exchange Commission (SEC) from company insiders or beneficial owners | ViewVerify |
CME Earnings Estimation Breakdown
The calculation of CME's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of CME is estimated to be 2.95 with the future projection ranging from a low of 2.7089 to a high of 3.35. Please be aware that this consensus of annual earnings estimates for CME Group is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
2.71 Lowest | Expected EPS | 3.35 Highest |
CME Earnings Projection Consensus
Suppose the current estimates of CME's value are higher than the current market price of the CME stock. In this case, investors may conclude that CME is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and CME's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
| 18 | 94.27% | 2.8 | 2.95 | 9.93 |
CME Earnings per Share Projection vs Actual
Actual Earning per Share of CME refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering CME Group predict the company's earnings will be in the future. The higher the earnings per share of CME, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.CME Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as CME, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of CME should always be considered in relation to other companies to make a more educated investment decision.CME Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact CME's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-04-22 | 2025-03-31 | 2.8087 | 2.8 | -0.0087 | 0 | ||
2025-02-12 | 2024-12-31 | 2.4454 | 2.52 | 0.0746 | 3 | ||
2024-10-23 | 2024-09-30 | 2.66 | 2.68 | 0.02 | 0 | ||
2024-07-24 | 2024-06-30 | 2.53 | 2.56 | 0.03 | 1 | ||
2024-04-24 | 2024-03-31 | 2.45 | 2.5 | 0.05 | 2 | ||
2024-02-14 | 2023-12-31 | 2.28 | 2.37 | 0.09 | 3 | ||
2023-10-25 | 2023-09-30 | 2.22 | 2.25 | 0.03 | 1 | ||
2023-07-26 | 2023-06-30 | 2.2 | 2.3 | 0.1 | 4 | ||
2023-04-26 | 2023-03-31 | 2.38 | 2.42 | 0.04 | 1 | ||
2023-02-08 | 2022-12-31 | 1.88 | 1.92 | 0.04 | 2 | ||
2022-10-26 | 2022-09-30 | 1.94 | 1.98 | 0.04 | 2 | ||
2022-07-27 | 2022-06-30 | 1.93 | 1.97 | 0.04 | 2 | ||
2022-04-27 | 2022-03-31 | 2 | 2.11 | 0.11 | 5 | ||
2022-02-09 | 2021-12-31 | 1.64 | 1.66 | 0.02 | 1 | ||
2021-10-27 | 2021-09-30 | 1.56 | 1.6 | 0.04 | 2 | ||
2021-07-28 | 2021-06-30 | 1.61 | 1.64 | 0.03 | 1 | ||
2021-04-28 | 2021-03-31 | 1.75 | 1.79 | 0.04 | 2 | ||
2021-02-10 | 2020-12-31 | 1.37 | 1.39 | 0.02 | 1 | ||
2020-10-28 | 2020-09-30 | 1.41 | 1.38 | -0.03 | 2 | ||
2020-07-29 | 2020-06-30 | 1.62 | 1.63 | 0.01 | 0 | ||
2020-04-29 | 2020-03-31 | 2.23 | 2.33 | 0.1 | 4 | ||
2020-02-12 | 2019-12-31 | 1.54 | 1.52 | -0.02 | 1 | ||
2019-10-30 | 2019-09-30 | 1.76 | 1.9 | 0.14 | 7 | ||
2019-07-31 | 2019-06-30 | 1.76 | 1.76 | 0.0 | 0 | ||
2019-05-01 | 2019-03-31 | 1.6 | 1.62 | 0.02 | 1 | ||
2019-02-14 | 2018-12-31 | 1.72 | 1.77 | 0.05 | 2 | ||
2018-10-25 | 2018-09-30 | 1.43 | 1.45 | 0.02 | 1 | ||
2018-07-26 | 2018-06-30 | 1.72 | 1.74 | 0.02 | 1 | ||
2018-04-26 | 2018-03-31 | 1.83 | 1.86 | 0.03 | 1 | ||
2018-02-01 | 2017-12-31 | 1.09 | 1.12 | 0.03 | 2 | ||
2017-10-26 | 2017-09-30 | 1.16 | 1.19 | 0.03 | 2 | ||
2017-08-01 | 2017-06-30 | 1.21 | 1.23 | 0.02 | 1 | ||
2017-04-27 | 2017-03-31 | 1.2 | 1.22 | 0.02 | 1 | ||
2017-02-02 | 2016-12-31 | 1.11 | 1.14 | 0.03 | 2 | ||
2016-10-27 | 2016-09-30 | 1.04 | 1.05 | 0.01 | 0 | ||
2016-07-28 | 2016-06-30 | 1.11 | 1.14 | 0.03 | 2 | ||
2016-04-28 | 2016-03-31 | 1.15 | 1.15 | 0.0 | 0 | ||
2016-02-05 | 2015-12-31 | 0.9 | 0.92 | 0.02 | 2 | ||
2015-10-29 | 2015-09-30 | 0.99 | 1.02 | 0.03 | 3 | ||
2015-07-30 | 2015-06-30 | 0.92 | 0.95 | 0.03 | 3 | ||
2015-04-30 | 2015-03-31 | 0.95 | 0.98 | 0.03 | 3 | ||
2015-02-05 | 2014-12-31 | 0.93 | 0.95 | 0.02 | 2 | ||
2014-10-30 | 2014-09-30 | 0.83 | 0.84 | 0.01 | 1 | ||
2014-07-31 | 2014-06-30 | 0.79 | 0.77 | -0.02 | 2 | ||
2014-05-01 | 2014-03-31 | 0.83 | 0.83 | 0.0 | 0 | ||
2014-02-04 | 2013-12-31 | 0.68 | 0.64 | -0.04 | 5 | ||
2013-11-04 | 2013-09-30 | 0.73 | 0.75 | 0.02 | 2 | ||
2013-08-01 | 2013-06-30 | 0.89 | 0.93 | 0.04 | 4 | ||
2013-05-02 | 2013-03-31 | 0.73 | 0.73 | 0.0 | 0 | ||
2013-02-05 | 2012-12-31 | 0.63 | 0.63 | 0.0 | 0 | ||
2012-10-25 | 2012-09-30 | 0.69 | 0.7 | 0.01 | 1 | ||
2012-07-26 | 2012-06-30 | 0.82 | 0.89 | 0.07 | 8 | ||
2012-04-26 | 2012-03-31 | 0.8 | 0.8 | 0.0 | 0 | ||
2012-02-02 | 2011-12-31 | 0.73 | 0.71 | -0.02 | 2 | ||
2011-11-01 | 2011-09-30 | 0.94 | 0.95 | 0.01 | 1 | ||
2011-07-28 | 2011-06-30 | 0.83 | 0.88 | 0.05 | 6 | ||
2011-04-28 | 2011-03-31 | 0.84 | 0.87 | 0.03 | 3 | ||
2011-02-03 | 2010-12-31 | 0.76 | 0.75 | -0.01 | 1 | ||
2010-10-28 | 2010-09-30 | 0.73 | 0.73 | 0.0 | 0 | ||
2010-07-29 | 2010-06-30 | 0.88 | 0.89 | 0.01 | 1 | ||
2010-04-29 | 2010-03-31 | 0.72 | 0.72 | 0.0 | 0 | ||
2010-02-04 | 2009-12-31 | 0.69 | 0.67 | -0.02 | 2 | ||
2009-10-29 | 2009-09-30 | 0.66 | 0.67 | 0.01 | 1 | ||
2009-07-23 | 2009-06-30 | 0.65 | 0.67 | 0.02 | 3 | ||
2009-04-23 | 2009-03-31 | 0.64 | 0.64 | 0.0 | 0 | ||
2009-02-03 | 2008-12-31 | 0.69 | 0.72 | 0.03 | 4 | ||
2008-10-29 | 2008-09-30 | 0.8 | 0.83 | 0.03 | 3 | ||
2008-07-22 | 2008-06-30 | 0.77 | 0.79 | 0.02 | 2 | ||
2008-04-22 | 2008-03-31 | 0.96 | 0.93 | -0.03 | 3 | ||
2008-02-05 | 2007-12-31 | 0.72 | 0.75 | 0.03 | 4 | ||
2007-10-24 | 2007-09-30 | 0.82 | 0.86 | 0.04 | 4 | ||
2007-07-24 | 2007-06-30 | 0.73 | 0.74 | 0.01 | 1 | ||
2007-04-24 | 2007-03-31 | 0.72 | 0.74 | 0.02 | 2 | ||
2007-01-30 | 2006-12-31 | 0.6 | 0.58 | -0.02 | 3 | ||
2006-10-24 | 2006-09-30 | 0.57 | 0.59 | 0.02 | 3 | ||
2006-07-25 | 2006-06-30 | 0.62 | 0.62 | 0.0 | 0 | ||
2006-04-25 | 2006-03-31 | 0.53 | 0.52 | -0.01 | 1 | ||
2006-01-31 | 2005-12-31 | 0.42 | 0.44 | 0.02 | 4 | ||
2005-10-25 | 2005-09-30 | 0.44 | 0.44 | 0.0 | 0 | ||
2005-07-26 | 2005-06-30 | 0.48 | 0.47 | -0.01 | 2 | ||
2005-04-26 | 2005-03-31 | 0.39 | 0.41 | 0.02 | 5 | ||
2005-02-01 | 2004-12-31 | 0.34 | 0.33 | -0.01 | 2 | ||
2004-10-26 | 2004-09-30 | 0.33 | 0.34 | 0.01 | 3 | ||
2004-07-22 | 2004-06-30 | 0.33 | 0.33 | 0.0 | 0 | ||
2004-04-27 | 2004-03-31 | 0.24 | 0.27 | 0.03 | 12 | ||
2004-02-03 | 2003-12-31 | 0.18 | 0.17 | -0.01 | 5 | ||
2003-10-22 | 2003-09-30 | 0.18 | 0.19 | 0.01 | 5 | ||
2003-07-22 | 2003-06-30 | 0.19 | 0.21 | 0.02 | 10 | ||
2003-04-22 | 2003-03-31 | 0.13 | 0.15 | 0.02 | 15 | ||
2003-01-30 | 2002-12-31 | 0.18 | 0.18 | 0.0 | 0 |
CME Corporate Directors
| Hilda Piell | Chief Human Resource Officer, Senior Managing Director | Profile | |
| Jack Tobin | Chief Accounting Officer, Managing Director | Profile | |
| Derek Sammann | Senior Managing Director - Financial Products and Services | Profile | |
| Julie Winkler | Senior Managing Director - Research and Product Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Financial Exchanges & Data space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.115 | Dividend Share 4.7 | Earnings Share 9.93 | Revenue Per Share | Quarterly Revenue Growth 0.104 |
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.